- Carlyle (CG) confirms that it has agreed to acquire Johnson & Johnson's (JNJ +0.3%) Ortho-Clinical Diagnostics (OCD) business for $4.15B.
- "This transaction is a result of our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson," J&J CEO Alex Gorsky says.
- OCD provides products for screening, diagnosing, monitoring and confirming diseases, including blood-screening equipment and laboratory blood tests. It's a smallish player in a market led by Roche, Siemens and Abbott Labs. (PR)
This was corrected on 01/16/2014 at 08:12 AM.
From other sites
at CNBC.com (May 12, 2015)
at CNBC.com (Mar 23, 2015)
at CNBC.com (Mar 3, 2015)
Video at CNBC.com (Mar 3, 2015)
at CNBC.com (Feb 24, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs